Abstract
Introduction:South Africa has the largest HIV epidemic of the world, but predictors of unsuppressed viral load among MSM are scarce.Methods:We did a cross-sectional study to assess socio-demographic characteristics, year of antiretroviral therapy (ART) initiation, and viral load data from 1385 MSM registered in five key population clinics in five districts in South Africa in 2023 and 2024. We used logistic regression to assess predictors of unsuppressed viral load (≥200 copies/ml). We then conducted a case - control study involving 57 cases (viral load≥200 copies/ml) and 57 matched controls (viral load<200 copies/ml; matched on age, ART start date, clinic, and outreach vs. facility attendance) drawn from the cross-sectional study to explore additional differences between groups.Results:In the cross-sectional study, predictors for unsuppressed viral load included on ART for 1-2 years [odds ratio (OR) 3.53; 1.77-7.69] or 3-5 years (OR 2.33; 1.18-5.04) vs. more than 5 years, being an outreach vs. facility-based client (OR: 2.64; 1.79-3.94), and enrolled at Johannesburg (OR: 3.53; 2.25-5.64), or Durban (OR: 0.36; 0.84-0.70), vs. Pretoria. The case-control study identified predictors for unsuppressed viral load, which included missing more than four ART dosages per month (OR: 5.55; 1.19-41,03), having moderate to severe anxiety (OR: 3.90; 1.34-12,52), hazardous alcohol use (OR: 2.70; 1.14-6.81), and Christian vs. no religion (OR: 3.89; 1.34-12.29).Conclusion:We identified regional differences and key predictors of unsuppressed viral load among MSM living with HIV in South Africa. Screening for risk factors for unsuppressed viral load at ART continuation may inform where adherence support and other health services are needed.
| Original language | English |
|---|---|
| Pages (from-to) | 1290-1296 |
| Journal | AIDS |
| Volume | 39 |
| Issue number | 9 |
| Early online date | 9 Apr 2025 |
| DOIs | |
| Publication status | Published - 15 Jul 2025 |
Bibliographical note
Publisher Copyright:© 2025 The Author(s).
Funding
Funding for the study was provided in part through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), which is funded by the Science for Africa Foundation to the Developing Excellence in Leadership, Training and Science in Africa (DELTAS Africa) program [Del-22-007] with support from Wellcome Trust and the UK Foreign, Commonwealth & Development Office and is part of the EDCPT2 program supported by the European Union; the Bill & Melinda Gates Foundation [INV-033558]; and Gilead Sciences Inc. [19275]. All content contained within is that of the authors and does not necessarily reflect positions or policies of any SANTHE funder. D.O. and E.J.S. were supported in part by NIH grant R34MH135806. All authors thank Dr Thomas H. Wieringa for his statistical consultation during the manuscript.
| Funders | Funder number |
|---|---|
| Science for Africa Foundation | |
| European Commission | |
| Wellcome Trust | |
| Bill and Melinda Gates Foundation | INV-033558 |
| Gilead Sciences | 19275 |
| National Institutes of Health | R34MH135806 |
Keywords
- HIV
- MSM
- South Africa
- adherence
- antiretroviral therapy
- anxiety
- medication adherence
- mental health
- unsuppressed viral load